Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release
Authors:
- 1 December 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 268, 390-399
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31771034, 31470922)
This publication has 44 references indexed in Scilit:
- Bioengineered and biohybrid bacteria-based systems for drug deliveryAdvanced Drug Delivery Reviews, 2016
- Analysis of nanoparticle delivery to tumoursNature Reviews Materials, 2016
- Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (Salmonella Typhimurium)Sensors and Actuators B: Chemical, 2016
- Engineered bacteria as therapeutic agentsCurrent Opinion in Biotechnology, 2015
- Intratumoral injection of Clostridium novyi -NT spores induces antitumor responsesScience Translational Medicine, 2014
- Bio‐Hybrid Cell‐Based Actuators for MicrosystemsSmall, 2014
- Evaluation of Clostridium novyi–NT spores in dogs with naturally occurring tumorsAmerican Journal of Veterinary Research, 2012
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011
- Strategies in the design of nanoparticles for therapeutic applicationsNature Reviews Drug Discovery, 2010
- Bacteria in cancer therapy: a novel experimental strategyJournal of Biomedical Science, 2010